FDA grants fast track designation for Priothera’s AML therapy
The new investigational drug, also known as KRP203, is a synthetic, sphingosine 1-phosphate receptor (S1PR) modulator. It has been evaluated in Phase I and Phase II trials for
The US Food and Drug Administration (FDA) has granted approval for Cosette Pharmaceuticals’ Evoxac oral solution to treat dry mouth symptoms in adults diagnosed with Sjögren’s disease.
Under the collaboration, the company will use its AI drug discovery platform along with Denali Therapeutics’ expertise across the blood-brain barrier (BBB) and neurodegeneration for identifying therapeutically relevant